Alba M, Fintini D, Sagazio A, et al
Vis-a-vis, the FDA and the CV discussions, we are essentially have had very constructive dialog with the agency, where basically they are confirming that we have promising data with the SUSTAIN 6, however they need some kind of confirmation before we can have a CV indication for Ozempic and that confirmation can actually come in the form of either a bridging study even with an oral route of administration of semaglutide such as the so-called oral trial
Neurology 40:767
Patients who notice sudden mood changes, increased anxiety, or withdrawal symptoms during tirzepatide titration should contact their psychiatrist immediately
Together, they can help combat oxidative stress that can occur during intense physical activity
Switching between medications is common but requires a careful plan